Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MRD-guided BR De-intensification in iNHL
NCT06557330Phase 2Not yet recruiting
- Sponsor
- Fox Chase Cancer Center
- Start
- Jun 2025
- Primary completion
- Sep 2027
- Modality
- Small Molecules, Monoclonal Antibodies
01
Overview
A Phase 2 trial of bendamustine, rituximab in Indolent Non-Hodgkin Lymphoma (INHL), sponsored by Fox Chase Cancer Center. Planned start Jun 2025; status: not yet recruiting.
02
Drugs
bendamustinerituximab
03
Conditions
Indolent Non-Hodgkin Lymphoma (INHL)
Beyond the preview
Go deeper on NCT06557330.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06557330.